Mineralocorticoid receptor: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (14 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load=' | <StructureSection load='' size='350' side='right' caption='Glycosylated human mineralocorticoid receptor ligand-binding domain complex with aldosterone, glycerol and sulfate (PDB entry [[2aa2]])' scene='78/781019/Cv/1'> | ||
== Function == | == Function == | ||
'''Mineralocorticoid receptor''' (MR) in epithelial cells is activated by the mineralocorticoid hormone aldosterone promoting renal sodium retention and potassium excretion. | '''Mineralocorticoid receptor''' (MR) in epithelial cells is activated by the mineralocorticoid hormone aldosterone promoting renal sodium retention and potassium excretion. It is [[Nuclear receptors|nuclear receptor]]. In non epithelial cells MR is activated by cortisol<ref>PMID:15199296</ref>. MR is exposed to many steroids including cortisol, cortisone and progesterone, however, aldosterone and deoxycorticosterone are its physiological ligands. | ||
See also [[Mineralocorticoids]]; [[Steroid Hormones and their receptors]] and [[Intracellular receptors]] | |||
== Disease == | == Disease == | ||
| Line 16: | Line 18: | ||
== Structural highlights == | == Structural highlights == | ||
The MR ligand aldosterone binds in a fully enclosed pocket, contacting residues with six α-helices and a β-turn. It forms hydrogen bonds with 4 MR residues<ref>PMID:15967794</ref>. | The MR ligand aldosterone binds in a <scene name='78/781019/Cv/6'>fully enclosed pocket, contacting residues with six α-helices and a β-turn</scene> ({{Template:ColorKey_Helix}}, {{Template:ColorKey_Strand}}, {{Template:ColorKey_Loop}}, | ||
{{Template:ColorKey_Turn}}). <scene name='78/781019/Cv/7'>It forms hydrogen bonds with 4 MR residues</scene><ref>PMID:15967794</ref>. <scene name='78/781019/Cv/8'>Whole binding site</scene>. Water molecules are shown as red spheres. | |||
</StructureSection> | </StructureSection> | ||
| Line 24: | Line 27: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
*Mineralocorticoid receptor DNA-binding site residues 593- | *Mineralocorticoid receptor DNA-binding site residues 593-671 | ||
671 | |||
**[[4tnt]] – hMR DBD + DNA - human<br /> | **[[4tnt]] – hMR DBD + DNA - human<br /> | ||
| Line 37: | Line 39: | ||
**[[2ab2]], [[3vhu]], [[2oax]] – hMR LBD (mutant) + spironolactone <br /> | **[[2ab2]], [[3vhu]], [[2oax]] – hMR LBD (mutant) + spironolactone <br /> | ||
**[[3wff]], [[3wfg]], [[4pf3]], [[3vhv]], [[5hcv]] – hMR LBD (mutant) + antagonist <br /> | **[[3wff]], [[3wfg]], [[4pf3]], [[3vhv]], [[5hcv]] – hMR LBD (mutant) + antagonist <br /> | ||
**[[2a3i]] – hMR LBD (mutant) + NCOA1 peptide <br /> | **[[6l88]] – hMR LBD (mutant) + esaxerenone<br /> | ||
**[[5l7e]], [[5l7g]], [[5l7h]], [[4uda]], [[4udb]] – hMR LBD + NCOA1 peptide + antagonist<br /> | **[[5mwy]], [[6gev]] – hMR LBD + NCOA1 peptide <br /> | ||
**[[2a3i]], [[5mwp]] – hMR LBD (mutant) + NCOA1 peptide <br /> | |||
**[[5l7e]], [[5l7g]], [[5l7h]], [[4uda]], [[4udb]], [[6gg8]], [[6ggg]] – hMR LBD + NCOA1 peptide + antagonist<br /> | |||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||